Browse Studies — Arctuva

Phase 1

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worl…

Non Small Cell Lung Carcinoma

Estimated

~$10 – $7,500

AbbVieNCT06772623

Phase 1

Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Sur…

Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small Cell LungNon-Small Cell Lung Carcinoma+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06694454

Quality Improvement Study of a New Generation of Whole Body PET Scanners

The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn …

Non Small Cell Lung Carcinoma NSCLCHead and Neck CancerProstate Cancer

Estimated

~$10 – $750

Memorial Sloan Kettering Cancer CenterNCT07690917

Phase 1

PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition

The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carc…

Non Small Cell Lung CarcinomaRenal Cell Carcinoma

Estimated

~$10 – $6,250

University of California, San DiegoNCT07219576